Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance

British Journal of Haematology

Volumn 150, Issue 2, 2010, Pages 240-242

  Breccia, Massimo ^a   Bocchia, Monica ^b   Cannella, Laura ^a   Defina, Marzia ^b   Ippoliti, Micaela ^b   Loglisci, Giuseppina ^a   Santopietro, Michelina ^a   Lauria, Francesco ^b   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

chronic myeloid leukaemia; Imatinib; vaccine

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CMLVAX100 PEPTIDE VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; PEPTIDE VACCINE; UNCLASSIFIED DRUG; VAXB2A2 25 PEPTIDE VACCINE;

ADULT; AMINO ACID SEQUENCE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMPLETE CYTOGENETIC RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNE RESPONSE; LETTER; LEUKOCYTE COUNT; MAJOR MOLECULAR RESPONSE; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; CANCER VACCINES; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES;

EID: 77954346869     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08187.x     Document Type: Letter

References (9)

1. Apperley, J.F. (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncology, 8, 1018 1029.
2. Bocchia, M., Gentili, S., Abruzzese, E., Fanelli, A., Iuliano, F., Tabilio, A., Amabile, M., Forconi, F., Gozzetti, A., Raspadori, D., Amadori, S. Lauria, F. (2005) Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet, 365, 657 662.
3. Chen, C.I., Maecker, H.T. Lee, P.P. (2008) Development and dynamics of robust T cell responses to CML under imatinib treatment. Blood, 111, 5342 5349.
4. Deininger, M.W., O' Brien, S.G., Guilhot, F., Goldman, J.M., Hochhaus, A., Hughes, T.P., Radich, J.P., Hatfield, A.K., Mone, M., Filian, J., Reynolds, J., Gathmann, I., Larson, R.A. Druker, B.J. (2009) International randomized study of interferon vs STI571(IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood, 114, 1126.
5. Guilhot, F., Roy, L., Saulnier, P.J., Guilhot, J., Barra, A., Gombert, J.M. Turhan, A. (2009) Immunotherapeutic approaches in chronic myelogenous leukemia. Leukaemia & Lymphoma, 49, 629 634.
6. Jain, N., Reuben, J.M., Kantarjian, H., Li, C., Gao, H., Lee, B.N., Cohen, E.N., Ebarb, T., Scheinberg, D.A. Cortes, J. (2009) Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer, 115, 3924 3934.
7. Kim, P.S., Lee, P.P. Levy, D. (2008) Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Computational Biology, 4, e100009514.
8. Michor, F., Hughes, T.P., Iwasa, Y., Branford, S., Shah, N.P., Sawyers, C.L. Nowak, M.A. (2005) Dynamics of chronic myeloid leukaemia. Nature, 435, 1267 1270.
9. Roeder, I., Horn, M., Glauche, I., Hochhaus, A., Mueller, M.C. Loeffler, M. (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: functi onal insights and clinical implications. Nature Medicine, 12, 1181 1184.